Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

Inclusion Criteria:

• Healthy children

Exclusion Criteria:

• known hypersensitivity to any vaccine component
• significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the past 14 days
• ascertained or suspected disease caused by N. meningitidis
• household contact with or intimate exposure to an individual with a positive culture of N. meningitidis serogroup C within the previous 60 days